Clinical Report: Dry Eye: Conquering Coexisting Diseases

Overview

Glaucoma patients exhibit a higher prevalence of dry eye disease (DED), which can complicate diagnosis and treatment. Alternative therapies such as selective laser trabeculoplasty and non-preserved medications may improve outcomes for these patients.

Background

Dry eye disease is a significant concern in glaucoma management due to its high prevalence among these patients. Topical glaucoma medications, particularly those containing preservatives, can exacerbate DED symptoms, complicating both diagnosis and treatment. Understanding the interplay between DED and glaucoma is crucial for optimizing patient care and ensuring accurate monitoring of disease progression.

Data Highlights

No specific numerical data provided in the article.

Key Findings

• Glaucoma patients have a higher prevalence of dry eye disease compared to non-glaucoma individuals.
• Topical glaucoma medications containing preservatives, such as benzalkonium chloride, can exacerbate DED symptoms.
• Selective laser trabeculoplasty (SLT) can lower intraocular pressure (IOP) by 20-30% in approximately 80% of patients.
• Minimally invasive glaucoma surgery (MIGS) may reduce the need for drops, thereby decreasing side effects associated with topical treatments.
• Virtual reality headset-based perimetry shows potential benefits in improving tear film stability and test reliability.
• Alternative treatment options for glaucoma patients with DED include sustained-release drug delivery platforms and non-preserved glaucoma medications.

Clinical Implications

Clinicians should consider alternative treatment modalities for glaucoma patients with coexisting DED to minimize the impact of medications on ocular surface health. Staying informed about advancements in glaucoma management can enhance patient outcomes and adherence to treatment.

Conclusion

Addressing the challenges of managing glaucoma in patients with dry eye disease requires innovative approaches and a thorough understanding of the latest treatment options. Effective management strategies can improve both ocular health and patient quality of life.

References

1. Nijm LM, Schweitzer J, Gould Blackmore J. Clin Ophthalmol, 2023 -- Glaucoma and Dry Eye Disease: Opportunity to Assess and Treat.
2. Camp AS, Long CP, Galor A, et al. J Glaucoma, 2022 -- Dry Eye Symptom Severity and Visual Field Reliability Metrics.
3. Walsh K, Jones L. Clin Ophthalmol, 2019 -- The use of preservatives in dry eye drops.
4. Bedrood S, Berdahl J, Sheybani A, Singh IP. Clin Ophthalmol, 2023 -- Alternatives to Topical Glaucoma Medication for Glaucoma Management.
5. Ophthalmology Management — Dry eye as a comorbidity
6. Ophthalmology Management — Treating Dry Eye: An Opportunity to Build Patient Loyalty
7. Ophthalmic Professional — Systemic meds can trigger dry eye
8. Contact Lens Spectrum — Dry Eye Dx and Tx
9. Dry eye as a comorbidity
10. Treating Dry Eye: An Opportunity to Build Patient Loyalty
11. Systemic meds can trigger dry eye
12. TFOS DEWS III: Executive Summary
13. Update information | Glaucoma: diagnosis and management | Guidance | NICE
14. Travoprost Intracameral Implant for Open-Angle Glaucoma or Ocular Hypertension: 12-Month Results of a Randomized, Double-Masked Trial - PMC